Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-41-729-7194
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding AG (NASDAQ:EARS) released its earnings results on Thursday, November, 15th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
2 brokers have issued 1 year target prices for Auris Medical's shares. Their forecasts range from $2.50 to $5.00. On average, they anticipate Auris Medical's share price to reach $3.75 in the next year. This suggests a possible upside of 752.3% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
Media coverage about EARS stock has been trending negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Auris Medical earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Are investors shorting Auris Medical?
Auris Medical saw a decline in short interest in December. As of December 14th, there was short interest totalling 982,848 shares, a decline of 30.2% from the November 30th total of 1,408,198 shares. Based on an average trading volume of 1,921,204 shares, the days-to-cover ratio is currently 0.5 days. Currently, 4.2% of the company's stock are sold short. View Auris Medical's Current Options Chain.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Sesen Bio (SESN), Arcturus Therapeutics (ARCT), Vistagen Therapeutics (VTGN), Forward Pharma A/S (FWP), Evoke Pharma (EVOK), Catabasis Pharmaceuticals (CATB), OncoSec Medical (ONCS), Nemus Bioscience (NMUS), Selecta Biosciences (SELB), Trevena (TRVN), VIVUS (VVUS), Leap Therapeutics (LPTX), DiaMedica Therapeutics (DMCAF), Adial Pharmaceuticals (ADIL) and ContraFect (CFRX).
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
- Mr. Hernan Levett CPA, Chief Financial Officer (Age 43)
- Colleen A. DeVries, SVP of Cogency Global Inc.
- Ms. Michelle Aarts Ph.D., Adviser
- Mr. Giles Hardingham Ph.D., Adviser
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $0.44.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $14.84 million. The biotechnology company earns $-24,800,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Auris Medical employs 24 workers across the globe.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
